Use of Collagen and HA-based Biomaterials to Be Prominent in Joint Reconstructive Surgeries: Fact.MR Report

The Collagen And HA-Based Biomaterials Market Is Expanding Quickly Due To Their Wide Use In Cosmetic Surgeries And Kneecap Treatments

Dublin, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Sales of collagen and HA-based biomaterials are predicted to progress at a CAGR of 6% from 2022 to 2027 and reach a market valuation of US$ 10.8 billion by 2027, reveals Fact.MR, a market research and competitive intelligence provider.

The most prevalent extracellular matrix protein in the animal kingdom, collagen, is a member of the fibrous protein family that helps tissues transmit weight and gives cells a highly biocompatible environment. Collagen is the ideal biomaterial for implantable medical devices and scaffolds for in vitro testing systems due to its great biocompatibility.

Mammal skin and tendons, which are rich in collagen, are rigorously processed by chemical and physical methods to produce collagen-based solutions, membranes, porous sponges, and threads for dental and surgical uses or cell culture matrices. Several collagen-rich tissues are utilized in the manufacturing of medical items for use in surgery, such as soft tissue augmentation to speed up wound healing, dental applications, and other uses.

Implants made from tissues, either human or animal sources, are produced by biomedical companies. These tissues are frequently processed and treated in a variety of methods. Market-available medical goods made from collagen are manufactured and purified using standard techniques. Reconstructive surgery is where they are successfully used, and the list of potential uses is growing. Collagen can be made into a wide variety of materials with a wide range of qualities by varying the preparation and processing methods.

The global market for collagen and HA-based biomaterials is anticipated to increase over the forecast period as a result of quick technological advancements for effective medical results, advancements in biomaterial products for arthritis by top industry players, rise in facial cosmetic surgeries, and growing awareness regarding the benefits offered by these biomaterials.

Get a Sample PDF of This Research Report with a Detailed Table of Content:

Huge Arthritis Patients Populace Moving towards Viscosupplementation

During viscosupplementation, a gel-like material (hyaluronic acid) is pushed into the kneecap, which helps to reduce pain in joints. Companies that produce viscosupplementation devices are scrambling to create and obtain new drug approvals for the treatment of elbow, hip, and knee osteoarthritis.

Viscosupplementation for knee osteoarthritis is projected to be a key growth driver, followed by hip osteoarthritis. The major justification is that viscosupplementation can reduce the chances of knee surgery.

Anti-inflammatory medications now include viscosupplementation. Manufacturers are concentrating their efforts on creating and promoting innovative viscosupplementation solutions in response to the rising demand for viscosupplementation devices.

Key Takeaways from Market Study

  • Sales of facial aesthetics dermal fillers are predicted to increase at a CAGR of 6.5% from 2022 to 2027.
  • The global collagen and HA-based biomaterials market is currently valued at US$ 8 billion.
  • Demand for viscosupplements is anticipated to expand at a CAGR of 6% during the forecast period.
  • China is predicted to be a profitable market for collagen and HA-based biomaterials due to the rise in anti-ageing treatments.

Winning Strategy

Based on characteristics, such as company overview, product offerings, financial analysis, recent advancements, and competitive marketing strategies, key competitors in the worldwide collagen and HA-based biomaterials market have been profiled in this report.

The medical needs of patients experiencing joint and mobility-related problems, which are anticipated to be common and increase in the future and place significant financial pressure on the world's market, are drawing manufacturers' attention evermore.

  • Galderma stated in February 2021 that the U.S. Food and Drug Administration (FDA) authorized Restylane® Defyne for the augment and improvement of mild to average chin retrusion in individuals over the age of 21.

Speak to Analyst:

Collagen and HA-based Biomaterials Industry Research Segments

  • By Type :
    • Facial Aesthetics Dermal Fillers
    • Viscosupplements
    • Viscoelastics
    • Wound Dressings
    • Others
  • By Application :
    • Food
    • Medicine
    • Cosmetics
  • By Region :
    • North America
    • Latin America
    • Europe
    • East Asia
    • South Asia & Oceania
    • MEA

More Valuable Insights on Offer

Fact.MR, in its new offering, presents an unbiased analysis of the global collagen and HA-based biomaterials market, presenting historical demand data (2017-2021) and forecast statistics for the period of 2022-2027.

The study divulges essential insights on the market on the basis of type (facial aesthetics dermal fillers, viscosupplements, viscoelastics, wound dressings, others) and application (food, medicine, cosmetics), across five major regions of the world (North America, Europe, Asia Pacific, Latin America, and MEA).

Quick Buy: Collagen and HA-based Biomaterials Market Research Report

Competitive Landscape

Major firms in the collagen and HA-based biomaterials market are focusing on creating advanced biomaterials. They are also employing growth strategies such as mergers and acquisitions, new product launches, partnerships, and more.

The competitive landscape section includes key global growth strategies, market dominance, and market ranking analysis of major companies such as Galderma Laboratories L.P., Bausch Health Companies Inc., Anika Therapeutics, Inc., Collagen Solutions Plc, Abbott Laboratories, Johnson & Johnson Services, Inc., Allergan plc, Sanofi, and BioCell Technology LLC.

  • A global unique developmental and commercialization contract for dermal and soft tissue filler solutions was signed by CollPlant Biotechnologies (NASDAQ: CLGN) and Allergan Aesthetics, an AbbVie company, in February 2021.
  • In February 2020, Anika Therapeutics, Inc., a leading privately held provider of joint surface and preservation solutions for active patients, announced the acquisition of Arthrosurface. Anika Therapeutics, Inc. is a global, integrated joint regenerative and preservation therapies manufacturer.
  • Allergan Aesthetics, an AbbVie corporation, announced the release of the SkinMedica® Neck Correct Cream in April 2021. This is the first item in the line's skilful skincare collection designed to treat the unique anatomy of the skin on the neck and decolletage. The SkinMedica® Neck Correct Cream was created for both, curing and preventing the initial signs of mild to serious neck degeneration.

Check out more related studies published by Fact.MR Research: 

Antimicrobial Regenerative Wound Matrix Market: Antimicrobial Regenerative Wound Matrix is a very important part of the wound care industry and global trade. Antimicrobial Regenerative Wound matrix is used to improve the regeneration of dermal and epidermal layers in both acute and acute wounds. Antimicrobial Regenerative Wound Matrix is an extracellular matrix (ECM) based scaffolds that have very high biocompatibility properties and biodegradability features for tissue regeneration. Rise in sedentary lifestyle, chronic illnesses can lead to the development of chronic wounds and ulcers giving rise to antimicrobial regenerative wound matrix market

Vascular Dressings Market: Vascular dressings are the dressing used for protection of vascular site having injury. Vascular dressings are also known as intravenous site dressings as these are used to prevent infections that can occur in the insertion site. These are important since the IV sites are prone to bacterial and viral infections. The major driver for the global market of vascular dressings will be hospital acquired infections at needle site.

Advanced Wound Care Market: The advance wound care market is poised to leverage at a CAGR of ~4% between 2020 and 2030. Rising incidence of type-1 diabetes has augmented treatment for diabetic ulcers. Presently, more than 4.5 million patients with diabetic pressure ulcers require treatment. Moreover, a significant number of patients suffer from venous ulcers. These surging incidences of chronic wound conditions is poised to leverage the advance wound care market to a very large extent.

Next Generation Wound Closure Device MarketAccording to latest research study by Fact.MR, next generation wound closure device market is set to witness numerous opportunities during forecast period. These devices are highly been utilized in surgical procedure to prevent the formation of skin gaps and bacterial infection. Rising demand from healthcare sector is predicted to give numerous opportunities to the product development in upcoming years and shall witness absolute $ opportunity of US$ 250 Mn.

About Us: 

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner. 

Mahendra Singh 
US Sales Office: 
11140 Rockville Pike 
Suite 400 
Rockville, MD 20852 
Tel: +1 (628) 251-158